Core Viewpoint - The Chinese innovative pharmaceutical sector is experiencing a downturn in stock indices, yet there is significant capital inflow into innovative drug ETFs, indicating a potential investment opportunity in the long term [1]. Group 1: Market Performance - The CSI Hong Kong Stock Connect Healthcare Comprehensive Index fell by 4.7%, while the Hang Seng Hong Kong Stock Connect Innovative Drug Index decreased by 4.3% [1]. - The CSI Innovative Drug Industry Index declined by 1.5%, and the CSI Biotechnology Theme Index dropped by 1.2% [1]. - The CSI 300 Healthcare Index saw a smaller decline of 0.8% [1]. - Despite the overall market downturn, the E Fund Hong Kong Stock Connect Innovative Drug ETF (159316) recorded a net subscription of 34 million units throughout the day [1]. Group 2: Industry Growth and Valuation - The total value of License-out transactions for Chinese innovative drugs has increased from $2.562 billion in 2017 to $140.274 billion by 2025, reflecting enhanced international competitiveness [1]. - By 2025, over 70% of innovative drug companies are expected to achieve positive revenue growth, indicating that the industry is entering a commercialization phase [1]. - The current valuation of the pharmaceutical sector is considered attractive, with recommendations to focus on companies with clear overseas expansion opportunities and those with clinical data advantages in specific segments [1].

Group 1 - The pharmaceutical sector led the market today, with significant gains in medical services and CRO concepts, as evidenced by the rise in various indices [1] - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index and the CSI Biotech Theme Index both increased by 1.9%, while the CSI 300 Pharmaceutical Health Index rose by 1.7% [1] - Active trading was noted in related ETFs, with the Hong Kong Stock Connect Innovative Drug ETF (159316) and the Pharmaceutical ETF (512010) achieving transaction volumes of 820 million and 1.09 billion respectively, indicating increased market activity [1] Group 2 - According to Zhongtai Securities, multiple factors are driving a gradual recovery in demand for CRO and CDMO within the pharmaceutical sector, alongside a continuous supply-side clearance over the past three years [1] - The sector is expected to experience a "Davis Double Play," where both profitability and valuation are anticipated to improve [1]